RADX vs NVS vs BMY vs PFE vs JNJ

For growth investors, Radiopharm Theranostics Limited (RADX) is the stronger pick with 1114% revenue growth year-over-year, versus -1.

6% for Pfizer Inc. (PFE). Bristol-Myers Squibb Company (BMY) offers the better valuation at 16. 3x trailing P/E (8. 9x forward), making it the more compelling value choice. Analysts rate Johnson & Johnson (JNJ) a "Buy" — based on 40 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Bristol-Myers Squibb Company (BMY) is the cheapest at 16.

3x versus Johnson & Johnson at 38. 2x. On forward P/E, Pfizer Inc. is actually cheaper at 8. 7x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Novartis AG wins at 1. 09x versus Johnson & Johnson's 34. 02x — a reasonable growth-adjusted valuation.

Over the past 5 years, Novartis AG (NVS) delivered a total return of +95.

1%, compared to -77. 4% for Radiopharm Theranostics Limited (RADX). Over 10 years, the gap is even starker: NVS returned +179. 4% versus RADX's -77. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Johnson & Johnson (JNJ) is the lower-risk stock at 0.

04β versus Radiopharm Theranostics Limited's 0. 80β — meaning RADX is approximately 1688% more volatile than JNJ relative to the S&P 500. On balance sheet safety, Johnson & Johnson (JNJ) carries a lower debt/equity ratio of 51% versus 3% for Bristol-Myers Squibb Company — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Radiopharm Theranostics Limited (RADX) is pulling ahead at 1114% versus -1.

6% for Pfizer Inc. (PFE). On earnings-per-share growth, the picture is similar: Bristol-Myers Squibb Company grew EPS 178. 2% year-over-year, compared to -57. 8% for Johnson & Johnson. Over a 3-year CAGR, RADX leads at 643. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Novartis AG (NVS) is the more profitable company, earning 25.

6% net margin versus -1055. 3% for Radiopharm Theranostics Limited — meaning it keeps 25. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NVS leads at 31. 2% versus -1050. 6% for RADX. At the gross margin level — before operating expenses — NVS leads at 75. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Novartis AG (NVS) is the more undervalued stock at a PEG of 1. 09x versus Johnson & Johnson's 34. 02x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Pfizer Inc. (PFE) trades at 8. 7x forward P/E versus 19. 1x for Johnson & Johnson — 10. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for JNJ: 12. 6% to $249. 27.

In this comparison, PFE (6.

7% yield), BMY (4. 4% yield), NVS (2. 8% yield), JNJ (2. 2% yield) pay a dividend. RADX does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Johnson & Johnson (JNJ) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

04), 2. 2% yield, +131. 3% 10Y return). Both have compounded well over 10 years (JNJ: +131. 3%, RADX: -77. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: RADX is a small-cap high-growth stock; NVS is a large-cap quality compounder stock; BMY is a mid-cap deep-value stock; PFE is a mid-cap income-oriented stock; JNJ is a large-cap quality compounder stock. NVS, BMY, PFE, JNJ pay a dividend while RADX does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.